1. Home
  2. ACIU vs IMRX Comparison

ACIU vs IMRX Comparison

Compare ACIU & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.69

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

IMRX

Immuneering Corporation

HOLD

Current Price

$5.04

Market Cap

288.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACIU
IMRX
Founded
2003
2008
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.6M
288.6M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ACIU
IMRX
Price
$2.69
$5.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$10.00
$17.20
AVG Volume (30 Days)
223.6K
626.9K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$706.75
N/A
Revenue Next Year
$321.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$3.86
52 Week High
$4.00
$10.08

Technical Indicators

Market Signals
Indicator
ACIU
IMRX
Relative Strength Index (RSI) 57.07 56.89
Support Level $2.57 $4.82
Resistance Level $3.13 $5.38
Average True Range (ATR) 0.17 0.22
MACD 0.02 0.02
Stochastic Oscillator 55.46 68.18

Price Performance

Historical Comparison
ACIU
IMRX

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: